Skip to main content
main-content

The independent medical news service

09-06-2019 | Oncology | Main feed | News

KEYNOTE-426 subgroup analyses confirm pembrolizumab–axitinib efficacy

Research presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA, adds support for use of pembrolizumab plus axitinib  as a first-line treatment for patients with metastatic renal cell carcinoma.

17-05-2019 | Oncology | News | Article

USA approves first-line avelumab–axitinib for advanced RCC

Click through to read more

29-04-2019 | Oncology | News | Article

FDA approves first-line pembrolizumab–axitinib for advanced RCC

Click through to read more

05-03-2019 | Kidney cancer | News | Article

Cabozantinib efficacy extends to non-clear-cell RCC

Almost three-quarters of patients with non-clear-cell renal cell carcinoma may benefit from treatment with the tyrosine kinase receptor inhibitor cabozantinib, suggesting its efficacy is not limited to clear-cell disease, say researchers.

21-02-2019 | Kidney cancer | News | Article

Immunotherapy-based regimens show promise in non-clear-cell RCC

Three trials point to the potential of regimens incorporating agents targeting the programmed cell death protein 1 or its ligand in patients with non-clear-cell renal cell carcinoma.

20-02-2019 | Kidney cancer | News | Article

Tivozanib improves refractory advanced RCC outcomes

The phase III TIVO-3 trial has found that both progression-free survival and response are significantly better with tivozanib than sorafenib in patients with refractory metastatic renal cell carcinoma.

Image Credits